close

Kendle International Inc., a clinical research organization, provides clinical development services on a contract basis to the biopharmaceutical industry worldwide. The company's clinical development services include clinical trial management, clinical data management, statistical analysis, medical writing, regulatory consulting and organizational meeting management, and publications services. It operates through two segments, Early Stage and Late Stage. The Early Stage segment focuses on its Phase I operations. The Late Stage segment comprises clinical development services related to Phase II through III clinical trials; late phase clinical development services related to Phase IIIB and IV clinical trials. It also provides regulatory expertise and consulting services at various stages of drug and device development; designs clinical programs and clinical trial protocols, reviews programs, and provides gap analysis; offers consulting services for nonclinical development for small molecules, biologicals, vaccines, and devices; assists in the U.S. Food and Drug Administration application process; and involves in collection, analysis, and reporting of drug safety data. In addition, this segment offers customized clinical data management with the ability to connect into and utilize a customer's own data systems. Kendle International operates in North America, Europe, Asia/Pacific, Latin America, and Africa. The company was founded in 1981 and is based in Cincinnati, Ohio.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	9999.99
Volume	298012
Volume Avg	(mio) 1098.07
52 Week High	7.68
52 Week Low	-0.59
PE	N/A
PE (group average)	39
EPS Year	0.00
EPS change Q/Q	-69.35%
EPS change Q/Q Yr ago	1000%
EPS change Q/Q next Q est	1000%
EPS change Y/Y	-1000%
REV change Q/Q	-6.3%
REV change Q/Q Yr ago	-11.86%
EPS next Q est	1.00
EPS next Y est	0.08
Divident Annual	0.00
Dividend Yield	0%